KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Palvella Therapeutics (PVLA) EBITDA Margin (2016 - 2024)

Palvella Therapeutics has reported EBITDA Margin over the past 9 years, most recently at 3812.79% for Q3 2022.

  • Quarterly EBITDA Margin fell 341461.0% to 3812.79% in Q3 2022 from the year-ago period, while the trailing twelve-month figure was 174.7% through Sep 2022, up 5040.0% year-over-year, with the annual reading at 142.0% for FY2021, 659.0% up from the prior year.
  • EBITDA Margin was 3812.79% for Q3 2022 at Palvella Therapeutics, up from 4637.39% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 27.34% in Q2 2018 and troughed at 4637.39% in Q2 2022.
  • The 5-year median for EBITDA Margin is 110.38% (2021), against an average of 717.04%.
  • Year-over-year, EBITDA Margin skyrocketed 192319bps in 2019 and then crashed -416683bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 1935.17% in 2018, then surged by 99bps to 11.98% in 2019, then plummeted by -7550bps to 916.53% in 2020, then soared by 88bps to 110.38% in 2021, then tumbled by -3354bps to 3812.79% in 2022.
  • Per Business Quant, the three most recent readings for PVLA's EBITDA Margin are 3812.79% (Q3 2022), 4637.39% (Q2 2022), and 45.29% (Q1 2022).